Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2 μg/5 μg, 10 μg/5 μg, and 40 μg/10 μg) of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide for 14 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Oct 2014 New trial record